Bone Biologics Corporation (BBLG)

The chart shows the growth of $10,000 invested in Bone Biologics Corporation in Oct 2022 and compares it to the S&P 500 index or another benchmark. It would be worth nearly $22 for a total return of roughly -99.78%. All prices are adjusted for splits and dividends.

Bone Biologics Corporation had a return of 8.57% year-to-date (YTD) and -91.94% in the last 12 months. Over the past 10 years, Bone Biologics Corporation had an annualized return of -95.68%, outperforming the S&P 500 benchmark which had an annualized return of -2.58%.

The Sharpe ratio shows whether the portfolio's excess returns are due to smart investment decisions or a result of taking a higher risk. The higher a portfolio's Sharpe ratio, the better its risk-adjusted performance.

The current Bone Biologics Corporation Sharpe ratio is -0.90. A negative Sharpe ratio means that the risk-free rate is higher than the portfolio's return. This value does not convey any meaningful information.

The chart below displays rolling 12-month Sharpe Ratio.

The Drawdowns chart displays portfolio losses from any high point along the way.

The table below shows the maximum drawdowns of the Bone Biologics Corporation. A maximum drawdown is an indicator of risk. It shows a reduction in portfolio value from its maximum due to a series of losing trades.

The maximum drawdown since January 2010 for the Bone Biologics Corporation is 99.87%, recorded on Dec 28, 2022. The portfolio has not recovered from it yet.

Current Bone Biologics Corporation volatility is 59.85%. The chart below shows the rolling 10-day volatility. Volatility is a statistical measure showing how big price swings are in either direction. The higher asset volatility, the riskier it is, because the price movements are less predictable.